KFC Tablet contains Ketoconazole 200 mg, an antifungal agent belonging to the imidazole class, primarily used for the treatment of various fungal infections. Ketoconazole exerts its effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including dermatophytosis, candidiasis, and pityriasis versicolor. KFC Tablet is particularly effective against infections caused by Candida species, dermatophytes, and Malassezia furfur. It is administered orally and should be taken with food to enhance absorption. The dosage and duration of therapy depend on the type and severity of the infection, and treatment should be continued for the prescribed period to prevent relapse. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as headache and dizziness. Hepatotoxicity is a rare but serious side effect; therefore, liver function tests should be monitored during prolonged therapy. KFC Tablet is contraindicated in patients with known hypersensitivity to ketoconazole or other azole antifungals and should be used cautiously in individuals with liver impairment. It is essential to avoid concomitant use with drugs that prolong the QT interval or are metabolized by CYP3A4 to prevent potential drug interactions.